Digoxin is Not Related to Mortality in Patients with Heart Failure: Results from the SELFIE-TR Registry

Basit Öğe Kaydı
dc.contributor.authorGuvenc, Rengin cetin
dc.contributor.authorGuvenc, Tolga Sinan
dc.contributor.authorCaglar, Mert Efe
dc.contributor.authorAl Arfaj, Abdullah Ayar
dc.contributor.authorBehrad, Ailin
dc.contributor.authorYilmaz, Mehmet Birhan
dc.date.accessioned2024-05-19T14:50:27Z
dc.date.available2024-05-19T14:50:27Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractAimsDigoxin has been used in the treatment for heart failure for centuries, but the role of this drug in the modern era is controversial. A particular concern is the recent observational findings suggesting an increase in all-cause mortality with digoxin, although such observations suffer from biased results since these studies usually do not provide adequate compensation for the severity of disease. Using a nationwide registry database, we aimed to investigate whether digoxin is associated with 1-year all-cause mortality in patients with heart failure irrespective of phenotype.MethodsA total of 1014 out of 1054 patients in the registry, of whom 110 patients were on digoxin, were included in the study. Multivariable adjustments were done and propensity scores were calculated for various prognostic indicators, including signs and symptoms of heart failure and functional capacity. Crude mortality, mortality adjusted for covariates, mortality in the propensity score-matched cohort, and Bayesian factors (BFs) were analyzed.ResultsCrude 1-year mortality rate did not differ between patients on and off digoxin (17.3% vs 20.1%, log-rank p = 0.46), and digoxin was not related to mortality following multivariable adjustment (hazard ratio 0.87, 95% confidence interval 0.539-1.402, p = 0.57). Similarly, all-cause mortality was similar in 220 propensity-score adjusted patients (17.3% vs 20.0%, log-rank p = 0.55). On Bayesian analyses, there was moderate to strong evidence suggesting a lack of difference between in unmatched cohort (BF10 0.091) and weak-to-moderate evidence in the matched cohort (BF10 0.296).ConclusionsIn this nationwide cohort, we did not find any evidence for an increased 1-year mortality in heart failure patients on digoxin.en_US
dc.identifier.doi10.1007/s40256-024-00639-3
dc.identifier.issn1175-3277
dc.identifier.issn1179-187X
dc.identifier.pmid38573460en_US
dc.identifier.scopus2-s2.0-85189473321en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org10.1007/s40256-024-00639-3
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5715
dc.identifier.wosWOS:001197103000001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAdis Int Ltden_US
dc.relation.ispartofAmerican Journal of Cardiovascular Drugsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectClinical-Outcomesen_US
dc.subjectTherapyen_US
dc.subjectAssociationen_US
dc.subjectWithdrawalen_US
dc.titleDigoxin is Not Related to Mortality in Patients with Heart Failure: Results from the SELFIE-TR Registryen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu